- Home
- NA vs ATOS Comparison
NA vs ATOS Comparison
Compare NA & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NA | ATOS |
|---|---|---|
| Founded | 2019 | 2009 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.4M | 36.2M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | NA | ATOS |
|---|---|---|
| Price | $2.95 | $5.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.67 |
| AVG Volume (30 Days) | 47.5K | ★ 98.2K |
| Earning Date | 01-01-0001 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,758.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.75 | $0.53 |
| 52 Week High | $31.48 | $7.56 |
Technical Indicators
Market Signals| Indicator | NA | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 43.67 | 68.21 |
| Support Level | $2.78 | $0.68 |
| Resistance Level | $3.42 | $5.12 |
| Average True Range (ATR) | 0.15 | 0.35 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 31.24 | 82.20 |
Price Performance
Historical ComparisonAbout NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.